newsfilter
← Latest News
Business Wire·

Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases

Intracranial Objective Response Rate of 30.2% was observed in 43 evaluable patients Results to be shared in poster presentation at ESMO Congress 2026 Taiho Oncology, Inc. and Cullinan Therapeutics, Inc.